Drugs / MK-2048
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04319718 | Aug 2020 → Feb 2022 | — | Hillier, Sharon, PhD | Completed | No outcome recorded |
| Phase 1 | NCT02419456 | Jun 2015 → Mar 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2048 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02419456 ↗ |
| Action | Inhibit | “the Integrase Inhibitor MK-2048” NCT04319718 ↗ |
| Route | Other | “single dose of a vaginal film containing MK-2048” NCT04319718 ↗ |